| KP | Kaufmann-Peterson [base]; keratitic precipitate; keratitis punctata; kidney protein; killed parenter... |
|---|---|
| KPV | key process variable; killed parenteral vaccine |
| KV | kanamycin and vancomycin; killed vaccine |
| MKV | killed measles vaccine |
| MMR | mass miniature radiography; masseter muscle rigidity; maternal mortality rate; measles-mumps-rubella... |
| smallpox vaccine | A live vaccinia virus vaccine of calf lymph or chick embryo origin, used for immunization against smallpox. It is now recommended only for laboratory workers exposed to smallpox virus. Certain countries continue to vaccinate those in the military service. Complications that result from smallpox vaccination include vaccinia, secondary bacterial infections, and encephalomyelitis. (12 Dec 1998) |
|---|---|
| split-virus vaccine | <pharmacology> A vaccine composed of a purified antigenic determinant that is separated from the disease-causing organism. (06 Mar 1998) |
| staphylococcus vaccine | A suspension of organisms from cultures of one or more strains of Staphylococcus; used for furunculosis, acne, and other suppurative conditions. (05 Mar 2000) |
| stock vaccine | A vaccine made from a stock microbial strain, in contradistinction to an autogenous vaccine. (05 Mar 2000) |
| subunit vaccine | <pharmacology> A vaccine composed of a purified antigenic determinant that is separated from the disease-causing organism. (06 Mar 1998) |
| diphtheria-tetanus-pertussis vaccine | A vaccine consisting of diphtheria toxoid, tetanus toxoid, and pertussis vaccine. It is usually given to infants three times at two-month intervals, generally at 2, 4, and 6 months of age. The vaccine protects against diphtheria, tetanus, and whooping cough. In most cases the vaccine causes only a temporary fever and discomfort, but in a few cases serious neurological side effects have been observed. (12 Dec 1998) |
| DTP vaccine | A vaccination administered to infants for protection against diphtheria, pertussis (whooping cough) and tetanus. Vaccinations are typically administered at 2, 4, 6 and 15 months. A final vaccination is now recommended at 4-6 years of age. (27 Sep 1997) |
| duck embryo origin vaccine | See: rabies vaccine. (05 Mar 2000) |
| inactivated polio vaccine | <pharmacology, virology> An inactivated vaccination, administered by injection to children for protection against the polio virus. Typically given at 2, 4 and 15 months. A final vaccine is recommended at 4-6 years. (27 Sep 1997) |
| inactivated poliovirus vaccine | Inactivated poliovirus vaccine (IPV), an aqueous suspension of inactivated strains of poliomyelitis virus (types 1, 2, and 3) used by injection; has largely been replaced by the oral vaccine. See: Salk vaccine. (05 Mar 2000) |
| influenza vaccine | A special vaccine which provides immunity to infection by a variety of Influenza viruses. The vaccine is updated annually due to the constant introduction of new viral strains. Flu vaccination programs are common in the elderly population and any other groups who are at increased risk of viral infection. (27 Sep 1997) |
| oil vaccine | A vaccine that contains an adjuvant; most often the antigen (immunogen) is included in a water-in-oil emulsion (Freund incomplete type adjuvant), or is adsorbed onto an inorganic gel (alum, aluminum hydroxide or phosphate). (05 Mar 2000) |
| TAB vaccine | A suspension of killed typhoid and paratyphoid A and B bacilli. See: typhoid vaccine. Synonym: TAB vaccine. (05 Mar 2000) |
| tetanus vaccine | See: diphtheria toxoid, tetanus toxoid, and pertussis vaccine. (05 Mar 2000) |
| therapeutic vaccine | An injected therapy consisting of synthetic HIV antigen (for example, gp160) that is administered to people who already have HIV It is supposed to heighten and broaden the immune response to HIV, helping to halt disease progression. (09 Oct 1997) |